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To investigate the role of innate immunity in variable efficacy of Mycobacterium bovis BCG vaccination in
Malawi and the United Kingdom, we examined 24-h tumor necrosis factor alpha, interleukin-1 (IL-1), and
IL-10 responses to mycobacterial purified protein derivatives (PPDs). The rank order in stimulatory potency
for different PPDs was the same for all three cytokines. Before vaccination Malawians made higher pro- and
anti-inflammatory responses than did United Kingdom subjects. Fewer than 5% of United Kingdom subjects
made IL-10 in response to any PPD, compared to 19 to 57% responders among Malawians. Priming for
regulatory IL-10 may contribute to the smaller increase in gamma interferon responses in Malawians com-
pared to United Kingdom subjects following BCG vaccination.
The efficacy of vaccination against tuberculosis with Myco-
bacterium bovis bacillus Calmette-Gue´rin (BCG) varies geo-
graphically (reviewed in reference 10), one reason for which
relates to differences in exposure to environmental mycobac-
teria (3). This is reflected in (i) higher prevaccination gamma
interferon (IFN-) responses to environmental mycobacterial
antigens in Malawi than in the United Kingdom (5), (ii)
greater BCG-attributable increases in IFN- responses in the
United Kingdom than in Malawi (5), and (iii) greater BCG-
attributable increases in IFN- response to M. tuberculosis
purified protein derivative (PPD) in Malawians with low initial
responsiveness to PPDs of M. avium, M. intracellulare, and M.
scrofulaceum (the MAIS complex) than in those with high
initial responses (3). The higher prevalence of IFN- respon-
siveness to PPDs of the environmental MAIS complex than to
PPDs of M. tuberculosis, M. bovis, or the more distantly related
fast-growing species M. vaccae and M. fortuitum in Malawi (3)
might relate to both relative exposure to these different species
and the composition of cross-reacting T-cell peptide epitopes
in the preparations. Alternatively, or in addition, they could
reflect the ability of PPDs to induce proinflammatory (e.g.,
tumor necrosis factor alpha [TNF-] and interleukin-1 [IL-
1]) or anti-inflammatory (e.g., IL-10) cytokine responses that
regulate the adaptive immune response. To address this, we
here examine 24-h TNF-, IL-1, and IL-10 responses in stim-
ulated whole-blood cultures. This reveals differences in the
magnitude of responsiveness to different mycobacterial PPDs
as well as apparent in vivo priming for higher prevaccination
responses in Malawian than in United Kingdom subjects.
Study design. Recruitment and study design are described in
detail elsewhere (4, 5, 23). In Malawi 633 young adults were
recruited: of 562 eligible for BCG vaccination, 378 received
BCG vaccine and 184 were given placebo. One year later, 329
of 378 vaccinees and 154 of 184 from the placebo group were
retested for cytokine responses. In the United Kingdom (5,
23), 424 children were recruited: of those eligible for BCG
vaccination, 282 received BCG vaccine and 115 controls re-
ceived no injection. One year later 246 of 282 vaccinees and
104 of 115 controls were retested. Individuals acting as placebo
group members or controls were vaccinated at the 1-year fol-
low-up. Whole-blood assays were performed as described else-
where (4, 5), and supernatants were collected 24 h poststimu-
lation with seven PPDs or one “new tuberculin,” derived from
six different species of mycobacteria. PPDs of M. tuberculosis
(batch RT48, lot 191), M. avium (batch RS10/2, lots 37 and 39),
M. intracellulare (batch RS23, lot 27), and M. scrofulaceum
(batch RS95, lots 17 and 18) were prepared (15) at the Statens
Serum Institut, Copenhagen, Denmark. M. avium CVL, a stan-
dard avian PPD (24) produced in 1954 at the Central Veteri-
nary Laboratory, was obtained from the Veterinary Laborato-
ries Agency. M. intracellulare PPD-B, prepared in 1970
according to a standard protocol (6), was obtained from the
U.S. Public Health Service. M. bovis CVL PPD was from the
National Institute of Biological Standards and Controls (South
Mimms, United Kingdom), and M. vaccae new tuberculin (20)
(batch R877R) was from J. Stanford (University College Lon-
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don). Endotoxin testing was carried out by the European En-
dotoxin Testing Service (Verviers, Belgium). Lipoarabinoman-
nan (LAM) content was measured by enzyme-linked
immunosorbent assay (ELISA) with antibody CS-35 (12),
which recognizes arabinofuranosyl-containing motifs on all
mycobacterial LAMs as the probe and BCG LAM as the stan-
dard. All preparations were used in whole-blood assays at a
final concentration of 5 g/ml. Lipopolysaccharide (LPS; Sig-
ma; final concentration, 1 g/ml) was used as a nonmycobac-
terial stimulus known to trigger innate immune responses.
Quantitative TNF-, IL-1, and IL-10 ELISAs were carried
out using commercially available antibody pairs (PharMingen,
San Diego, Calif.; Biosource, Nivelles, Belgium). Recombinant
cytokines (2,000 to 31 pg/ml; PharMingen or Biosource) were
used for the standard curves; the lower limit of detection for all
assays was 31 pg/ml. Plates were read and analyzed using Rev-
elation 3.04 software (Dynex, Chantilly, Va.). Medium-alone
negative-control values were subtracted from all results. Con-
trol supernatants were exchanged between the Malawi and
United Kingdom labs to ensure comparability. Statistical anal-
yses were carried out using STATA 7. Associations between
pairs of variables were quantified using the Spearman rank
correlation coefficient. Differences between the United King-
dom and Malawi were assessed using the Mann-Whitney test
for median responses and the chi-square test for the percent-
age with a “positive” (i.e., 62-pg/ml) response. Linear regres-
sion was used for analysis of the change in TNF- and IL-10
responses between recruitment and 1 year postvaccination.
Values below the limit of detection of the assay were set to 15
pg/ml. A log transformation (base 2) was used for both the
prevaccination and the postvaccination response. Analysis was
based upon the difference between these two values.
PPDs trigger higher prevaccination TNF-, IL-1, and
IL-10 responses in Malawi than in the United Kingdom. Pre-
vaccination inflammatory cytokine responses are presented as
median responses (picograms per milliliter) and percent re-
sponders (62 pg/ml) in Fig. 1. Two clear patterns emerge: (i)
the rank order of potency of the different mycobacterial prep-
arations is essentially the same for TNF-, IL-1, and IL-10
responses, and (ii) Malawians make higher pro- and anti-in-
flammatory responses than do United Kingdom individuals.
The latter is not due to differences in culture conditions, since
both populations made similar TNF-, IL-1, and IL-10 re-
sponses to control LPS stimulation (90% responders; data
not shown). Nor is the responsiveness to the mycobacterial
preparations due to LPS contamination, since the level of
endotoxin measured in all of the mycobacterial antigens used
here was0.05 endotoxin units/ml (5 pg/ml). The rank order
of potency of the PPD or new tuberculin preparations holds
true across both populations for TNF- and IL-1, with the
percentage of individuals responding to each of the antigens in
Malawi strongly correlated with the percentage of individuals
responding to the same antigens in the United Kingdom
(TNF-, r  0.97, P  0.001; IL-1, r  0.95, P  0.001). In
Malawi there were significant correlations (r  0.52 to 0.68, P
 0.001) for individual TNF- against IL-1 responses for all
seven PPDs and for M. vaccae new tuberculin. TNF- and
IL-1 responses each also were correlated (r  0.35 to 0.65, P
 0.001) with IL-10 responses. Among United Kingdom ado-
lescents, for whom all median responses were generally lower
(Fig. 1), the only moderately strong correlations were between
TNF- and IL-1 (r  0.51, P  0.001) for responses to M.
avium CVL and between TNF- and IL-10 (r  0.60, P 
0.001) and IL-1 and IL-10 (r  0.57, P  0.001) for responses
to M. vaccae new tuberculin. The prevalence of IL-10 respon-
siveness to PPDs was extremely low, with the exception of the
response to M. vaccae new tuberculin. Interestingly, M. vaccae
new tuberculin produced the highest TNF-, IL-1, and IL-10
responses in both populations, and M. tuberculosis PPD pro-
duced the lowest responses.
LAM content. The similar rank order of stimulatory potency
of PPDs suggests a common recognition and signaling pathway
and/or some interdependence among these cytokines for their
induction. Such coordinated regulation of all three cytokines
has been observed previously in the response of human mono-
cytes to bacterial LPS (11), where it was demonstrated that
IL-10 synthesis is uniquely dependent on endogenous proin-
flammatory cytokines TNF- and IL-1. LPS triggers macro-
phages through the combined action of the adaptor molecule
CD14 and the signal-transducing molecule Toll-like receptor 2
(TLR2) (1, 22). Mycobacteria also possess ligands that trigger
both TLR2 and TLR4 (reviewed in reference 21). The myco-
bacterial ligands for TLR2 include LAM, a biosynthetic pre-
cursor of LAM phosphatidylinositolmannan, and the 19-kDa
lipoprotein of M. tuberculosis, both of which could copurify
with proteins and/or peptides in the PPD preparative process.
LAM derived from ubiquitous, fast-growing, nonpathogenic
mycobacteria (PILAM or AraLAM) binds CD14 and TLR2
(21) and elicits potent pro- and anti-inflammatory responses.
The biochemically distinct (13) LAM from M. tuberculosis and
M. bovis (ManLAM) fails to activate TLR2- or TLR4-trans-
fected cells (21) and is a poor inducer of TNF-, IL-1, and
IL-10 responses. Using the CS-35 antibody, we found that all of
the mycobacterial PPDs contained LAM (Fig. 2) at concentra-
tions (364 to 757 ng/ml) of the order of magnitude (1,000
ng/ml) of purified LAM used previously (16, 17) to induce
macrophage pro- and anti-inflammatory responses. However,
since the CS-35 antibody binds less avidly to ManLAM than to
AraLAM (12) and mycobacteria differ in relative content of
ManLAM and AraLAM (13), the absolute amount of LAM
measured in the assay will not directly reflect its stimulatory
potency. Hence, although there was no direct correlation be-
tween the magnitude of cytokine responses elicited by the
different PPDs and LAM content as measured in our assay
(data not shown), the rank order of potency of the prepara-
tions does reflect the relative content of qualitatively different
LAMs. LAMs from different strains of M. tuberculosis (Erd-
man, H37Rv, and H37Ra) and attenuated M. bovis BCG are
all mannose capped but vary in the extent of capping between
40 and 70% (13). This is consistent with our observation that
PPDs from M. tuberculosis and M. bovis are at the bottom end
of the rank order for potency as triggers in our assays (Fig. 1).
In contrast, the more distantly related fast-growing M. vaccae
is likely, like other fast-growing strains, to have the arabinan
domain of LAM uncapped (AraLAM) or be capped with phos-
phoinositide motifs (PILAM) (13). This is consistent with its
position as the most potent trigger for all three cytokines in our
assays, despite the lower levels of LAM (217 ng/ml) detected
by our assay. Members of the MAIS (M. avium, M. intracellu-
lare, and M. scrofulaceum) complex are intermediate, both in
1808 NOTES INFECT. IMMUN.
FIG. 1. Median responses (picograms per milliliter) and percent responders (62 pg/ml) for seven mycobacterial PPDs and M. vaccae new
tuberculin. Data are presented in order of magnitude of TNF- responses. Group sizes were as stated previously except for IL-1 responses in
United Kingdom (UK) subjects, where n  100. SSI, Statens Serum Institut; CVL, Central Veterinary Laboratory.
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terms of their potency as triggers for pro- and anti-inflamma-
tory cytokines in our assays and in having LAMs capped mainly
with single mannose residues rather than the di- and triman-
nopyranoside motifs found in M. tuberculosis and M. bovis-
derived ManLAM (14). Overall our data are consistent with
the hypothesis that qualitatively different LAMs could be the
major contributors to the innate immune responses that we
have observed to be elicited by PPDs in whole-blood assays.
Effect of BCG vaccination on TNF-, IL-1, and IL-10 re-
sponses. Higher prevaccination pro- and anti-inflammatory re-
sponses in Malawian than in United Kingdom adolescents sug-
gested in vivo priming, possibly due to exposure to
environmental mycobacteria. To determine whether M. bovis
BCG vaccination itself could prime for enhanced inflammatory
responses, we compared pre- and postvaccination responses.
In order to determine whether there was a significant vaccine-
related change in response between years 1 and 2, we com-
pared (Table 1, vaccine/placebo ratio) how many times higher
(or lower) the vaccine-induced change was than the placebo.
For TNF- responses, there were no significant vaccine-related
changes in response to any antigens in Malawi or the United
Kingdom (Table 1, ratio of change in vaccinated group to
change in placebo group of close to 1). For IL-10 responses,
there was a vaccine-related reduction in response to M. bovis
and M. avium CVL PPDs (borderline significance; P  0.058;
P  0.065), M. scrofulaceum PPD (P  0.015), and M. vaccae
new tuberculin (P  0.02) in Malawi (Table 1, ratio of change
in vaccinated group to change in placebo group of 1) but no
vaccine-related change in response to any antigens in the
United Kingdom. Hence, although we were measuring imme-
diate (24-h) innate anti-inflammatory responses to mycobacte-
rial antigen preparations in vitro, there were changes in re-
sponses over the year in Malawi that appear to be attributable
to vaccine-induced in vivo effects that reduce IL-10 responses.
Conclusions. Recent research has focused on mechanisms
that allow innate immunity to drive and modulate the adaptive
immune response (2, 7–9, 18, 19), particularly in relation to M.
tuberculosis infection (21) and to vaccination (7). Innate im-
munity involves rapid recognition of pathogen-associated mo-
lecular patterns via pattern recognition receptors, leading to
the induction of inflammatory cytokines by macrophages and
expression of costimulatory molecules on dendritic cells. We
have shown that, in addition to providing protein antigens for
recall of adaptive T-cell IFN- responses (3, 4, 23), mycobac-
terial PPDs also elicit potent early-innate TNF-, IL-1, and
IL-10 responses in whole-blood assays. While we cannot dis-
count some role for dendritic cells and T cells in production of
24-h inflammatory cytokine responses, it seems likely that
monocytes dominate the response. This stimulation of innate
responses by mycobacterial PPDs may influence detection of
antigen-specific T-cell responses in whole-blood cultures.
An interesting feature of our study was the dramatic differ-
ence in pro- and anti-inflammatory responses between Malawi
and the United Kingdom. This could reflect a difference in the
relative numbers of circulating monocytes and/or expression of
higher levels of pattern recognition receptors on circulating
monocytes in Malawian than in United Kingdom adolescents.
FIG. 2. LAM concentrations, as determined by ELISA with anti-
LAM CS-35 antibody, which recognizes arabinofuranosyl-containing
motifs common to all LAMs, in seven mycobacterial PPDs and M.
vaccae new tuberculin. Data are presented in order of potency as
inducers of pro- and anti-inflammatory responses. SSI, Statens Serum
Institut; CVL, Central Veterinary Laboratory.
TABLE 1. Vaccination with M. bovis BCG and changes in proinflammatory (TNF-) or anti-inflammatory (IL-10) responses to mycobacterial
antigens as indicated by comparison of vaccine and placebo groupsa
Antigen
Response by cytokine and country
TNF- IL-10
Malawi UK Malawi UK
Vaccine/
placebo
ratio
95% CI P
Vaccine/
placebo
ratio
95% CI P
Vaccine/
placebo
ratio
95% CI P
Vaccine/
placebo
ratio
95% CI P
M. tuberculosis PPD (SSI) 1.17 0.86–1.59 0.315 1.14 0.88–1.48 0.318 0.97 0.82–1.15 0.741 0.97 0.86–1.09 0.562
M. bovis PPD (CVL) 1.04 0.71–1.53 0.843 1.31 1.03–1.67 0.071 0.84 0.70–1.01 0.058 0.87 0.84–1.12 0.664
M. avium PPD (CVL) 1.00 0.68–1.48 0.989 1.30 0.96–1.78 0.094 0.84 0.70–1.01 0.065 1.03 0.85–1.25 0.785
M. avium PPD (SSI) 0.97 0.76–1.24 0.799 1.21 0.91–1.62 0.188 0.97 0.80–1.18 0.740 1.10 0.79–1.53 0.556
M. intracellulare PPD (SSI) 0.83 0.63–1.09 0.178 1.26 0.93–1.71 0.128 0.90 0.76–1.05 0.185 1.05 0.83–1.34 0.660
M. intracellulare PPD-B 1.11 0.77–1.61 0.571 1.06 0.77–1.44 0.735 0.89 0.66–1.22 0.473 1.15 0.81–1.62 0.440
M. scrofulaceum PPD (SSI) 1.02 0.76–1.35 0.917 0.96 0.77–1.21 0.743 0.83 0.71–0.96 0.015 0.99 0.86–1.13 0.838
M. vaccae new tuberculin 0.88 0.67–1.15 0.346 1.19 0.79–1.78 0.406 0.79 0.64–0.96 0.020 0.92 0.57–1.50 0.741
a The vaccine/placebo ratio takes into account a comparison of year 1 and year 2 data for the same individual. Ratios of 1 indicate that vaccination is associated
with an enhanced response; ratios of 1 indicate that vaccination is associated with a reduced response. Significant (P  0.05) and borderline significant (0.05  P 
0.065) responses are shown by boldface. Abbreviations: SSI, Statens Serum Institut; CVL, Central Veterinary Laboratory; UK, United Kingdom; CI, confidence
interval.
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Of particular note was the failure of United Kingdom subjects
to make IL-10 in response to PPDs compared to Malawians. In
contrast, the apparent priming for immunoregulatory IL-10
responses in Malawians might contribute to smaller BCG vac-
cine-induced IFN- responses to M. tuberculosis PPD (3–5). As
our data suggest that BCG vaccination reduced the IL-10 re-
sponse to some PPDs in Malawians, this may be further evi-
dence of a role for in vivo priming and boosting of the innate
immune response.
In conclusion, our results demonstrate that mycobacterial
PPD preparations do contain molecules that act as ligands to
stimulate innate immune responses. Importantly, major differ-
ences detected in Malawi compared to the United Kingdom
indicate that in vivo priming for innate immune responses
occurs and may contribute to the mechanisms that determine
differences in levels of protection against M. tuberculosis fol-
lowing BCG vaccination in these two populations.
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